Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $48.17.

A number of equities research analysts recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Piper Jaffray Companies restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Cowen and Company restated a “positive” rating and set a $50.00 price objective (up from $40.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Janney Montgomery Scott initiated coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a “neutral” rating and a $47.00 price objective on the stock.

Shares of Supernus Pharmaceuticals (SUPN) traded up 0.41% during trading on Friday, hitting $49.05. The company had a trading volume of 1,026,254 shares. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $50.00. The stock has a market capitalization of $2.49 billion, a P/E ratio of 24.75 and a beta of 1.30. The firm’s 50 day moving average is $44.38 and its 200-day moving average is $37.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities research analysts anticipate that Supernus Pharmaceuticals will post $1.04 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Given Consensus Rating of “Buy” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/16/supernus-pharmaceuticals-inc-supn-given-consensus-rating-of-buy-by-analysts.html.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the completion of the transaction, the vice president now directly owns 24,944 shares in the company, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 160,000 shares of company stock worth $7,505,574. Company insiders own 6.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Sheets Smith Wealth Management bought a new position in Supernus Pharmaceuticals in the second quarter worth approximately $378,000. Turner Investments LLC bought a new position in Supernus Pharmaceuticals in the first quarter worth approximately $219,000. Bank of America Corp DE grew its stake in Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after purchasing an additional 35,069 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new position in Supernus Pharmaceuticals in the first quarter worth approximately $468,000. Finally, Dimensional Fund Advisors LP grew its stake in Supernus Pharmaceuticals by 3.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,146,040 shares of the specialty pharmaceutical company’s stock worth $35,871,000 after purchasing an additional 39,033 shares in the last quarter. 95.38% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.